这个日志已经过期。这里是 2020 年的更新。
---1st line---
RATIONALE 301 (百济神州/BeiGene) tislelizumab vs sorafenib
HIMALAYA (AstraZeneca) durvalumab or durvalumab+tremelimumab vs sorafenib
LEAP-002 (MSD+Eisai) lenvatinib + pembrolizumab vs lenvatinib
COSMIC-312 (Exelixis) cabozantinib + atezolizumab vs sorafenib vs cabozantinib
SHR-1210-III-310 (恒瑞) SHR-1210+apatinib vs sorafenib
EMERALD-1 (AstraZeneca) TACE+durvalumab±bevacizumab vs TACE + placebo
ORIENT-32 (信达/Innovent) sintilimab (IBI308)+IBI305 vs sorafenib
CheckMate 9DW (BMS) nivolumab + ipilimumab vs sorafenib
CS1003 (基石) CS1003 + lenvatinib vs placebo + lenvatinib
---2nd line---
KEYNOTE-394 (MSD) pembrolizumab vs placebo in Asian pts.
---Adjuvant---
CheckMate 9DX (BMS) nivolumab vs placebo
EMERALD-2 (AstraZeneca) durvalumab+bevacizumab vs durvalumab+placebo vs placebo
KEYNOTE-937 (MSD) pembrolizumab vs placebo
JUPITER 04 (君实/Junshi) Toripalimab vs placebo
IMbrave050 (Roche) atezolizumab + bevacizumab vs none therapy
